Abstract
High-density lipoprotein (HDL) cholesterol level is low in dialysis patients. The HDL that is present is dysfunctional, failing to protect low-density lipoprotein (LDL) from oxidation and reduce levels of oxidized LDL. Addition of the orally absorbable amphipathic peptide 4-F to LDL obtained from dialysis patients protects LDL from oxidation in vitro and reduces the capacity of oxidized LDL to induce expression of monocyte chemoattractant protein-1 (MCP-1) by vascular endothelial function in culture, potentially providing a tool to reduce cardiovascular risk in dialysis patients.
Original language | English (US) |
---|---|
Pages (from-to) | 359-361 |
Number of pages | 3 |
Journal | Kidney International |
Volume | 76 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2009 |
ASJC Scopus subject areas
- Nephrology